Valuation: Lundbeck

Market Cap 39.13B 6.03B 5.24B 4.88B 4.48B 8.48B 574B 8.57B 57.55B 22.5B 287B 22.64B 22.15B 950B P/E 2026 *
8.85x
P/E 2027 * 8.87x
Enterprise Value 43.21B 6.66B 5.78B 5.39B 4.95B 9.36B 633B 9.47B 63.55B 24.84B 317B 25B 24.45B 1,049B EV / Sales 2026 *
1.67x
EV / Sales 2027 * 1.51x
Free-Float
30.75%
Yield 2026 *
3.71%
Yield 2027 * 3.77%
1 day-0.56%
1 week-2.89%
Current month-2.08%
1 month-4.08%
3 months+1.15%
6 months+3.68%
Current year-2.62%
1 week 35.15
Extreme 35.15
36.65
1 month 35.15
Extreme 35.15
37.45
Current year 31.4
Extreme 31.4
39.9
1 year 28.65
Extreme 28.65
39.9
3 years 23.3
Extreme 23.3
41.7
5 years 21.94
Extreme 21.935
41.7
10 years 21.94
Extreme 21.935
41.7
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 66 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%-2.89% - - 6.03B
+0.40%-6.64%+16.81%+96.89% 97.22B
-0.87%+0.45%+47.24%+155.95% 54.7B
+0.34%0.00%+3.47%+277.22% 24.02B
-1.07%+1.09%-13.34%-16.77% 8.27B
-0.28%-1.45%-34.89%-30.97% 7.4B
-0.52%-2.49%-8.63%-17.22% 6.9B
-0.03%-4.25%-2.14%+22.73% 5.21B
-1.75%+0.80%-6.81%-5.60% 3.74B
-1.93%-11.44%+6.31%+14.54% 3.59B
Average -0.63%-1.94%+0.89%+55.20% 23.45B
Weighted average by Cap. -0.15%-2.96%+18.29%+115.01%

Financials

2026 *2027 *
Net sales 25.83B 3.98B 3.46B 3.22B 2.96B 5.6B 379B 5.66B 37.98B 14.85B 189B 14.94B 14.62B 627B 25.85B 3.98B 3.46B 3.22B 2.96B 5.6B 379B 5.66B 38.01B 14.86B 189B 14.96B 14.63B 628B
Net income 4.56B 703M 610M 569M 523M 988M 66.84B 999M 6.71B 2.62B 33.41B 2.64B 2.58B 111B 4.57B 704M 611M 570M 523M 990M 66.95B 1B 6.72B 2.63B 33.47B 2.64B 2.59B 111B
Net Debt 4.08B 628M 546M 509M 467M 884M 59.76B 893M 6B 2.34B 29.88B 2.36B 2.31B 98.99B -9.63M -1.48M -1.29M -1.2M -1.1M -2.09M -141M -2.11M -14.17M -5.54M -70.59M -5.57M -5.45M -234M
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
05/08/26 DKK 35.25 -0.70% 63,963
04/08/26 DKK 35.50 +0.28% 88,284
03/08/26 DKK 35.40 -1.67% 155,231
31/07/26 DKK 36.00 -0.28% 60,768
30/07/26 DKK 36.10 -0.55% 29,056
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
40.48DKK
Average target price
47.88DKK
Spread / Average Target
+18.27%

Quarterly revenue - Rate of surprise